“Bringing the experience and expertise from three additional DOE national laboratories to ATOM’s current partners,…, reinforces ATOM as a valuable national resource to create powerful new capabilities for the cancer research community, building collaborations and driving advances in translational research to develop treatments more quickly,” said Eric Stahlberg, director of the Biomedical Informatics and Data Science group at FNL and co-lead of the ATOM consortium.